Musclees and Cyclic GMP Regulation in Heart

[1]  F. Fedele,et al.  Chronic Inhibition of cGMP Phosphodiesterase 5A Improves Diabetic Cardiomyopathy: A Randomized, Controlled Clinical Trial Using Magnetic Resonance Imaging With Myocardial Tagging , 2012, Circulation.

[2]  Sang-Eun Lee,et al.  Long-Term Effects of Sildenafil in a Rat Model of Chronic Mitral Regurgitation: Benefits of Ventricular Remodeling and Exercise Capacity , 2012, Circulation.

[3]  S. Harding,et al.  Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig. , 2012, Life sciences.

[4]  D. Kass,et al.  Preconditioning by Phosphodiesterase‐5 Inhibition Improves Therapeutic Efficacy of Adipose‐Derived Stem Cells Following Myocardial Infarction in Mice , 2012, Stem cells.

[5]  B. French,et al.  Differential Expression of PDE5 in Failing and Nonfailing Human Myocardium , 2012, Circulation. Heart failure.

[6]  W. Linke,et al.  Sildenafil and B-Type Natriuretic Peptide Acutely Phosphorylate Titin and Improve Diastolic Distensibility In Vivo , 2011, Circulation.

[7]  Clint L. Miller,et al.  Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart , 2011, Basic Research in Cardiology.

[8]  D. Kass,et al.  Phosphodiesterases and cardiac cGMP: evolving roles and controversies. , 2011, Trends in pharmacological sciences.

[9]  A. Abbate,et al.  Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway. , 2011, American journal of physiology. Heart and circulatory physiology.

[10]  M. Zaccolo,et al.  cGMP Signals Modulate cAMP Levels in a Compartment-Specific Manner to Regulate Catecholamine-Dependent Signaling in Cardiac Myocytes , 2011, Circulation research.

[11]  J. Corbin,et al.  Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. , 2011, Physiological reviews.

[12]  R. Arena,et al.  PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.

[13]  M. Movsesian,et al.  Phosphodiesterase inhibition in heart failure. , 2011, Handbook of experimental pharmacology.

[14]  Saisudha Koka,et al.  Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor. , 2010, Molecular and cellular pharmacology.

[15]  Dong I. Lee,et al.  Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5. , 2010, Journal of the American College of Cardiology.

[16]  N. Etienne-Selloum,et al.  Concerted Regulation of cGMP and cAMP Phosphodiesterases in Early Cardiac Hypertrophy Induced by Angiotensin II , 2010, PloS one.

[17]  R. Fischmeister,et al.  Feedback Control Through cGMP-Dependent Protein Kinase Contributes to Differential Regulation and Compartmentation of cGMP in Rat Cardiac Myocytes , 2010, Circulation research.

[18]  S. Francis.  The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP. , 2010, Circulation research.

[19]  J. Beavo,et al.  Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy , 2010, Proceedings of the National Academy of Sciences.

[20]  H. Ke,et al.  Conformation Changes, N-terminal Involvement, and cGMP Signal Relay in the Phosphodiesterase-5 GAF Domain* , 2010, The Journal of Biological Chemistry.

[21]  Anindita Das,et al.  Long-Acting Phosphodiesterase-5 Inhibitor Tadalafil Attenuates Doxorubicin-Induced Cardiomyopathy without Interfering with Chemotherapeutic Effect , 2010, Journal of Pharmacology and Experimental Therapeutics.

[22]  D. Kass,et al.  TRP-ing up Heart and Vessels: Canonical Transient Receptor Potential Channels and Cardiovascular Disease , 2010, Journal of cardiovascular translational research.

[23]  Clint L. Miller,et al.  Targeting Cyclic Nucleotide Phosphodiesterase in the Heart: Therapeutic Implications , 2010, Journal of cardiovascular translational research.

[24]  M. Shattock,et al.  Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury , 2010, American journal of physiology. Heart and circulatory physiology.

[25]  Xinli Hu,et al.  Oxidative Stress Regulates Left Ventricular PDE5 Expression in the Failing Heart , 2010, Circulation.

[26]  M. Nishida,et al.  Phosphorylation of TRPC6 Channels at Thr69 Is Required for Anti-hypertrophic Effects of Phosphodiesterase 5 Inhibition* , 2010, The Journal of Biological Chemistry.

[27]  Dong I. Lee,et al.  PDE5A suppression of acute β-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation , 2010, Basic Research in Cardiology.

[28]  J. Pandit,et al.  Cyclic nucleotide binding GAF domains from phosphodiesterases: structural and mechanistic insights. , 2009, Structure.

[29]  A. Wojtovich,et al.  Role of Ca 2 (cid:1) /Calmodulin–Stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte Hypertrophy , 2009 .

[30]  K. Fennell,et al.  Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct , 2009, Proceedings of the National Academy of Sciences.

[31]  R. Arena,et al.  The impact of pharmacotherapy on the cardiopulmonary exercise test response in patients with heart failure: a mini review. , 2009, Current vascular pharmacology.

[32]  J. Corbin,et al.  cGMP-Hydrolytic Activity and Its Inhibition by Sildenafil in Normal and Failing Human and Mouse Myocardium , 2009, Journal of Pharmacology and Experimental Therapeutics.

[33]  Mark J. Kohr,et al.  Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes. , 2009, Journal of molecular and cellular cardiology.

[34]  D. Kass,et al.  Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. , 2009, Pharmacology & therapeutics.

[35]  D. Kass,et al.  Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. , 2009, Journal of molecular and cellular cardiology.

[36]  W. Linke,et al.  Titin-based mechanical signalling in normal and failing myocardium. , 2009, Journal of molecular and cellular cardiology.

[37]  H. Milting,et al.  Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling. , 2009, Cardiovascular research.

[38]  Lei Xi,et al.  ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. , 2009, American journal of physiology. Heart and circulatory physiology.

[39]  K. Sipido,et al.  Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice , 2009, Circulation.

[40]  D. Kass,et al.  Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. , 2009, Journal of the American College of Cardiology.

[41]  D. Kass,et al.  Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. , 2009, The Journal of clinical investigation.

[42]  D. Kass,et al.  Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. , 2008, Cardiovascular research.

[43]  Christian Andresen,et al.  Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs , 2008, Circulation research.

[44]  J. Nielsen-Kudsk,et al.  Effects of phosphodiesterase‐5 inhibition by sildenafil in the pressure overloaded right heart , 2008, European journal of heart failure.

[45]  D. Kass,et al.  Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. , 2008, Cellular signalling.

[46]  D. Thedens,et al.  Sarcolemma-localized nNOS is required to maintain activity after mild exercise , 2008, Nature.

[47]  D. Kass,et al.  Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil , 2008, Journal of Pharmacology and Experimental Therapeutics.

[48]  K. Nakao,et al.  Regulator of G-Protein Signaling Subtype 4 Mediates Antihypertrophic Effect of Locally Secreted Natriuretic Peptides in the Heart , 2008, Circulation.

[49]  F. Vandeput,et al.  Cyclic Nucleotide Phosphodiesterase PDE1C1 in Human Cardiac Myocytes* , 2007, Journal of Biological Chemistry.

[50]  R. Gerszten,et al.  Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007 .

[51]  A. Hatzelmann,et al.  Characterization of inhibitors of phosphodiesterase 1C on a human cellular system , 2007, The FEBS journal.

[52]  P. Light,et al.  Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility , 2007, Circulation.

[53]  Manuela Zaccolo,et al.  of in The Role of the in the A Molecular for Generating cAMP and cGMP Signaling Cross-Talk Role of Phosphodiesterases and Implications for Cardiac Pathophysiology , 2007 .

[54]  D. Kass,et al.  Compartmentalization of Cardiac &bgr;-Adrenergic Inotropy Modulation by Phosphodiesterase Type 5 , 2007 .

[55]  John McAnally,et al.  TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. , 2006, The Journal of clinical investigation.

[56]  Daniel Morton,et al.  Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian Species , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[57]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use , 2006, Pharmacological Reviews.

[58]  D. Cooper,et al.  Cyclic Guanosine Monophosphate Compartmentation in Rat Cardiac Myocytes , 2006, Circulation.

[59]  C. Lugnier.  Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. , 2006, Pharmacology & therapeutics.

[60]  M. Zaccolo,et al.  Compartmentalized Phosphodiesterase-2 Activity Blunts &bgr;-Adrenergic Cardiac Inotropy via an NO/cGMP-Dependent Pathway , 2006, Circulation research.

[61]  D. Kass,et al.  Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans , 2005 .

[62]  R. Fischmeister,et al.  Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. , 2005, Comparative biochemistry and physiology. Part A, Molecular & integrative physiology.

[63]  P. Fisher,et al.  Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity , 2005, Circulation.

[64]  Anindita Das,et al.  Phosphodiesterase-5 Inhibitor Sildenafil Preconditions Adult Cardiac Myocytes against Necrosis and Apoptosis , 2005, Journal of Biological Chemistry.

[65]  P. Fisher,et al.  Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. , 2005, Vascular pharmacology.

[66]  R. Zoraghi,et al.  Structural and Functional Features in Human PDE5A1 Regulatory Domain That Provide for Allosteric cGMP Binding, Dimerization, and Regulation* , 2005, Journal of Biological Chemistry.

[67]  J. Beavo,et al.  Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: modes of ligand binding and dimerization. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[69]  M. Zaccolo,et al.  cGMP Catabolism by Phosphodiesterase 5A Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism , 2004, Circulation research.

[70]  A. Y. Wu,et al.  Molecular Determinants for Cyclic Nucleotide Binding to the Regulatory Domains of Phosphodiesterase 2A* , 2004, Journal of Biological Chemistry.

[71]  J. Beavo,et al.  Regulation of Nitric Oxide–Sensitive Guanylyl Cyclase Cyclic GMP Phosphodiesterases and Regulation of Smooth Muscle Function Structure, Regulation, and Function of Membrane Guanylyl Cyclase Receptors, With a Focus on GC-A Cyclic GMP–Dependent Protein Kinases and the Cardiovascular System: Insights F , 2003 .

[72]  S. Balaji,et al.  Modeling and mutational analysis of the GAF domain of the cGMP‐binding, cGMP‐specific phosphodiesterase, PDE5 , 2003, FEBS letters.

[73]  A. Monfort,et al.  Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. , 2003, Biochemical and biophysical research communications.

[74]  P. Ferdinandy,et al.  Effect of classic preconditioning on the gene expression pattern of rat hearts: a DNA microarray study , 2003, FEBS letters.

[75]  J. Beavo,et al.  PDE5 is converted to an activated state upon cGMP binding to the GAF A domain , 2003, The EMBO journal.

[76]  J. Corbin,et al.  Sildenafil citrate does not affect cardiac contractility in human or dog heart , 2003, Current medical research and opinion.

[77]  K. Omori,et al.  cGMP-Phosphodiesterase Activity Is Up-regulated in Response to Pressure Overload of Rat Ventricles , 2003, Bioscience, biotechnology, and biochemistry.

[78]  A. Y. Wu,et al.  The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[79]  P. Greengard,et al.  Phosphodiesterase 1B Knock-Out Mice Exhibit Exaggerated Locomotor Hyperactivity and DARPP-32 Phosphorylation in Response to Dopamine Agonists and Display Impaired Spatial Learning , 2002, The Journal of Neuroscience.

[80]  J. Beavo,et al.  Cyclic Nucleotide Phosphodiesterase 1C Promotes Human Arterial Smooth Muscle Cell Proliferation , 2002, Circulation research.

[81]  J. Beavo,et al.  Upregulation of Phosphodiesterase 1A1 Expression Is Associated With the Development of Nitrate Tolerance , 2001, Circulation.

[82]  R. Fischmeister,et al.  Cyclic GMP regulation of the L‐type Ca2+ channel current in human atrial myocytes , 2001, The Journal of physiology.

[83]  A. Wilderspin,et al.  Cloning of dog heart PDE1A - a first detailed characterization at the molecular level in this species. , 2001, Gene.

[84]  G. D. Thomas,et al.  Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[85]  J. Corbin,et al.  Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. , 2000, European journal of biochemistry.

[86]  J. Corbin,et al.  Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.

[87]  K. Ferguson,et al.  Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase. , 1997, Gene.

[88]  K. Sadhu,et al.  Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3′,5′-Cyclic Nucleotide Phosphodiesterases (*) , 1996, The Journal of Biological Chemistry.

[89]  W. K. Sonnenburg,et al.  Identification of Inhibitory and Calmodulin-binding Domains of the PDE1A1 and PDE1A2 Calmodulin-stimulated Cyclic Nucleotide Phosphodiesterases (*) , 1995, The Journal of Biological Chemistry.

[90]  W. K. Sonnenburg,et al.  Molecular cloning of a cDNA encoding the "61-kDa" calmodulin-stimulated cyclic nucleotide phosphodiesterase. Tissue-specific expression of structurally related isoforms. , 1993, The Journal of biological chemistry.

[91]  C. Lugnier,et al.  Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. , 1986, Biochemical pharmacology.

[92]  R. Sharma,et al.  Differential regulation of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isoenzymes by cyclic AMP-dependent protein kinase and calmodulin-dependent phosphatase. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[93]  P. Hamet,et al.  Characteristics of a new binding protein distinct from the kinase for guanosine 3':5'-monophosphate in rat platelets. , 1980, Biochimica et biophysica acta.

[94]  T. Lincoln,et al.  Characterization of a novel cGMP binding protein from rat lung. , 1980, The Journal of biological chemistry.

[95]  J. Beavo,et al.  Stimulation of adenosine 3',5'-monophosphate hydrolysis by guanosine 3',5'-monophosphate. , 1971, The Journal of biological chemistry.